Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by ...
Ocugen (NASDAQ:OCGN) outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying ...
—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...
Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic area. Patients ...
Could a single border zone imaging measurement predict how quickly a geographic atrophy (GA) lesion will grow? A border zone ...
3 Lesser-Known Healthcare Names With Major Upside in Store Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl said ...
GA lesions, which form on the retina due to degeneration of pigment epithelium and photoreceptors, significantly impact daily functioning. This analysis assessed how functional and structural ...
Geographic atrophy (GA) is a late stage of age-related macular degeneration (AMD) associated with severe and irreversible, but gradual visual impairment. In its early stages, GA typically affects the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results